Abstract | BACKGROUND: Despite their broadly recommended use as chemotherapeutic agents, the porphyrogenicity of methotrexate and actinomycin D have not been confirmed. Accordingly, it is not known whether these agents are safe for use in patients with porphyria. CASE PRESENTATION: CONCLUSIONS:
|
Authors | Yukiko Mikami, Tomonori Nagai, Yousuke Gomi, Yasushi Takai, Masahiro Saito, Kazunori Baba, Hiroyuki Seki |
Journal | Journal of medical case reports
(J Med Case Rep)
Vol. 10
Pg. 9
(Jan 18 2016)
ISSN: 1752-1947 [Electronic] England |
PMID | 26781485
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antineoplastic Agents
- Chorionic Gonadotropin
- Dactinomycin
- Methotrexate
|
Topics |
- Antibiotics, Antineoplastic
(therapeutic use)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Chorionic Gonadotropin
(blood)
- Dactinomycin
(therapeutic use)
- Drug Eruptions
(drug therapy, etiology)
- Female
- Humans
- Hydatidiform Mole, Invasive
(drug therapy, secondary, surgery)
- Hysterectomy
- Lung Neoplasms
(drug therapy, secondary)
- Methotrexate
(administration & dosage, adverse effects)
- Middle Aged
- Porphyria, Acute Intermittent
(complications)
- Pregnancy
- Treatment Outcome
- Uterine Neoplasms
(drug therapy, pathology, surgery)
|